Related Experiment Videos
FCE 23884, substrate-dependent interaction with the dopaminergic system. II. Preclinical biochemical studies
N Carfagna1, C Caccia, S Mantegani
1R&D, Farmitalia Carlo Erba-Erbamont Group, Central Nervous System Department, Nerviano, MI, Italy.
The Journal of Pharmacology and Experimental Therapeutics
|October 1, 1991
Summary
FCE 23884 exhibits mixed dopamine (DA) antagonist and agonist effects. Its action depends on experimental conditions, influencing DA turnover and cyclic AMP levels differently in rats.
Area of Science:
- Neuropharmacology
- Biochemistry
Background:
- FCE 23884 is a novel compound with an ergoline structure.
- Understanding its receptor binding profile and in vivo effects is crucial for its potential therapeutic applications.
Purpose of the Study:
- To investigate the neurochemical effects of FCE 23884.
- To determine its dopamine (DA) receptor interactions and functional consequences.
Main Methods:
- In vitro receptor binding assays.
- Measurement of dopamine turnover and synthesis in rat brain regions.
- Assessment of adenylate cyclase activity and cyclic AMP formation.
- In vivo studies using normal and reserpinized rats.
Main Results:
- FCE 23884 showed high affinity for D-2, alpha-2, and 5-HT1A receptors.
- It increased DA turnover and synthesis in normal rats, indicating DA antagonism.
- It stimulated adenylate cyclase and cyclic AMP formation, suggesting DA agonism.
- In reserpinized rats, it decreased DA turnover and synthesis.
Conclusions:
- FCE 23884 displays mixed DA antagonist and agonist properties.
- Its pharmacological profile is context-dependent, influenced by the presence or absence of DA.
- These findings provide a neurochemical basis for its observed behavioral effects.